文献速递糖尿病

在澳大利亚全科医疗中对2型糖尿病成人每3个月使用专业模式瞬感血糖监测(GP-OSMOTIC):一项实用性、开放标签、12个月随机对照试验

Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-01-01

GP-OSMOTIC试验在澳大利亚维多利亚州25家全科诊所纳入299例2型糖尿病成人,随机分为专业模式瞬感血糖监测组(149例)与常规护理组(150例)。12个月时主要结局HbA1c组间差异无统计学显著(-0.3%,95%CI -0.5至0.01;p=0.059),但监测组目标血糖范围内时间百分比高7.9%(95%CI 2.3至13.5;p=0.0060),6个月时HbA1c较低(差异-0.5%,95%CI -0.8至-0.3;p=0.0001)。

要点

  • 12个月时主要结局HbA1c组间差异无统计学显著(-0.3%,95%CI -0.5至0.01;p=0.059)。
  • 12个月目标血糖范围内时间百分比监测组较常规护理组高7.9%(95%CI 2.3至13.5;p=0.0060)。
  • 6个月时监测组HbA1c较常规护理组低0.5%(95%CI -0.8至-0.3;p=0.0001),12个月糖尿病特异性痛苦评分无变化。

核心结论

  • 在澳大利亚全科医疗的2型糖尿病成人中,每3个月专业模式瞬感血糖监测与常规护理相比未改善12个月HbA1c主要结局或糖尿病特异性痛苦,但改善了12个月目标血糖范围内时间及6个月HbA1c。
  • 作者认为专业模式瞬感血糖监测可在实用性初级医疗环境中实施,目标范围内时间改善可能反映该技术通过提供血糖谱洞察支持个体化临床护理的潜力。

研究设计与样本

  • 实用性、双臂、开放标签、12个月、个体随机对照试验(GP-OSMOTIC),在澳大利亚维多利亚州25家全科诊所进行。
  • 纳入18-80岁成人,2型糖尿病确诊至少1年,过去1个月HbA1c至少高于目标5.5 mmol/mol(0.5%),尽管已处方至少两种非胰岛素降糖药、胰岛素或两者(治疗稳定至少4个月)。
  • 参与者按1:1随机分配至专业模式瞬感血糖监测系统组或常规临床护理(对照组),随机化在传感器佩戴后通过电子随机(区组大小4和6,按诊所分层)进行。
  • 监测组在基线及3、6、9、12个月全科就诊前佩戴专业模式瞬感血糖监测传感器5-14天,传感器每15分钟记录组织间液葡萄糖浓度,数据在全科就诊时由健康专业人员上传讨论。
  • 对照组在基线和12个月佩戴传感器仅用于数据分析,并每3个月进行常规护理访视;主要结局为12个月时平均HbA1c组间差异,分析按意向性治疗进行。

主要发现

  • 2016年10月4日至2017年11月17日随机分配299例成人:149例至瞬感血糖监测组,150例至常规护理组。
  • 6个月时HbA1c监测组低于常规护理组(差异-0.5%,95%CI -0.8%至-0.3%;p=0.0001)。
  • 12个月时主要结局估计平均HbA1c组间差异无统计学显著:监测组8.2%(95%CI 8.0至8.4)vs 常规护理组8.5%(95%CI 8.3至8.7),组间差异-0.3%(95%CI -0.5至0.01);66 mmol/mol(95%CI 64至68)vs 69 mmol/mol(95%CI 67至72),组间差异-3.0(95%CI -5.0至0.1);p=0.059。
  • 12个月目标血糖范围(4-10 mmol/L)内时间百分比监测组较常规护理组高7.9%(95%CI 2.3至13.5;p=0.0060)。
  • 12个月糖尿病特异性痛苦PAID评分无变化(组间差异-0.7,95%CI -3.3至1.9;p=0.61);未报告严重低血糖或治疗相关死亡,一例参与者死于与干预无关的原因(心肌梗死后并发症伴多种合并症)。

临床怎么用

  • 作者认为专业模式瞬感血糖监测可在实用性初级医疗环境中实施。
  • 作者指出尽管12个月HbA1c无变化,目标范围内时间改善可能反映该技术通过提供血糖谱洞察支持个体化临床护理的潜力。

局限性

  • 参与者与治疗临床医生无法对分组分配设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous glucose monitoring, either real-time (personal) or retrospective (professional mode), can identify day-to-day glucose profiles to guide management decisions for people with type 2 diabetes. We aimed to examine the effects of professional-mode flash glucose monitoring, done at 3-month intervals, in adults with type 2 diabetes in general practice. METHODS: We did a pragmatic, two-arm, open label, 12-month, individually randomised controlled trial (GP-OSMOTIC) in 25 general practices in Victoria, Australia. Eligible participants were adults aged 18-80 years, with type 2 diabetes diagnosed for at least 1 year and HbA1c at least 5·5 mmol/mol (0·5%) above their target in the past month despite being prescribed at least two non-insulin glucose-lowering drugs, insulin, or both (with therapy stable for at least 4 months). We randomly assigned participants (1:1) to either use of a professional-mode flash glucose monitoring system or usual clinical care (control). All participants wore the flash glucose monitoring sensor at baseline, and electronic randomisation (using permuted block sizes of four and six, and stratified by clinic) was done after the sensor was attached. Masking of participants and treating clinicians to group allocation was not possible, but the study statistician was masked to allocation when analysing the data. At baseline, and 3, 6, 9, and 12 months, participants in the flash glucose monitoring group wore the professional-mode flash glucose monitoring sensor for 5-14 days before their general practice visit. The sensor recorded interstitial glucose concentrations every 15 min, but the glucose data were not available to the participant until their general practice visit, where the sensor output would be uploaded to a computer by the health professional and discussed. Control group participants wore the sensor at baseline and at 12 months for data analysis only, and had usual care visits every 3 months. The primary outcome was the between-group difference in mean HbA1c at 12 months. Secondary outcomes were the between-group differences in: mean percentage time in target glucose range (4-10 mmol/L), based on ambulatory glucose profile data at 12 months; mean diabetes-specific distress (assessed with the Problem Areas In Diabetes [PAID] scale) at 12 months; and mean HbA1c at 6 months. Analysis was done by intention to treat. This trial is registered at the Australian and New Zealand Clinical Trials Registry, ACTRN12616001372471. FINDINGS: Between Oct 4, 2016, and Nov 17, 2017, we randomly assigned 299 adults: 149 to flash glucose monitoring and 150 to usual care. At 6 months, HbA1c was lower in the flash glucose monitoring group than in the usual care group (difference -0·5%, 95% CI -0·8% to -0·3%; p=0·0001). However, at 12 months (primary outcome), there was no significant between-group difference in estimated mean HbA1c (8·2% [95% CI 8·0 to 8·4] for flash glucose monitoring vs 8·5% [8·3 to 8·7] for usual care; between-group difference -0·3%, 95% CI -0·5 to 0·01; [66 mmol/mol, 95% CI 64 to 68 vs 69 mmol/mol, 67 to 72; between-group difference -3·0, 95% CI -5·0 to 0·1]; p=0·059). Mean percentage time spent in target glucose range at 12 months was 7·9% (95% CI 2·3 to 13·5) higher in the flash glucose monitoring group than in the usual care group (p=0·0060). Diabetes-specific distress PAID scores were unchanged at 12 months (between-group difference -0·7, 95% CI -3·3 to 1·9; p=0·61). No episodes of severe hypoglycaemia or treatment-related deaths were reported. One participant died during the study from causes unrelated to the intervention (following complications post-myocardial infarction with multiple comorbidities). INTERPRETATION: Professional-mode flash glucose monitoring in adults with type 2 diabetes in general practice did not improve the primary outcome of HbA1c at 12 months or diabetes-specific distress compared with usual care, but did improve time in target glucose range at 12 months and HbA1c at 6 months. Our findings suggest that professional-mode flash glucose monitoring can be implemented in a pragmatic primary care environment. Although there was no change in HbA1c at 12 months, the improved time in target range might reflect the potential of the technology to support personalised clinical care by providing insights into glycaemic profiles for some people with type 2 diabetes. FUNDING: National Health and Medical Research Council of Australia, Sanofi Australia, and Abbott Diabetes Care.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Furler J, O'Neal D, Speight J, et al. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes Endocrinol. 2020. PMID: 31862147. doi:10.1016/S2213-8587(19)30385-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。